Psoriasis has various systemic comorbidities including psychiatric disorders. Due to limited experience of dermatologists, psychiatric comorbidities are often not adequately addressed or treated. Recently, the association between depression, a risk factor for suicidality, and psoriasis has become a topic of interest due to suicides occurring in patients on new therapies such as apremilast and brodalumab for the treatment of psoriasis. A systematic literature search was conducted to provide an overview for clinicians on the epidemiological relationship between depression and psoriasis. Although there seems to be higher prevalence of depression in patients with psoriasis compared to non-psoriatic patients, the estimated prevalence of the comorbidity varies greatly and does not necessarily correlate with severity of psoriasis. Given the clear increased risk and association of depression with psoriasis, it is plausible that depression is not directly linked with the apremilast or brodalumab, but rather with psoriasis itself.